About Neuromod

Neuromod Devices Limited was founded in 2010 and is headquartered in Dublin, Ireland.

Neuromod is a pioneer in the development of non-invasive neuromodulation devices that target the auditory and trigeminal nerves to induce positive neuroplastic changes for sustained therapeutic benefit.
Clinically proven efficacy

The Lenire™ tinnitus treatment has been evaluated in four clinical trials conducted in Ireland and Germany. In the TENT-A1 and TENT-A2 double-blind clinical trials, 326 and 191 patients respectively were enrolled and randomised to one of three treatment arms in TENT-A1 and one of four treatment arms in TENT-A2. After patients had completed at least 10 weeks of self-administered treatment (30-60 minutes per day at home), the device was returned and patients followed for a further 12 months. The TENT-A1 clinical trial is complete and database lock is underway. The treatment phase of TENT-A2 is complete, with the 12 month follow up ongoing. Results from both trials will be submitted for peer-review following database lock.

Preliminary results from both trials indicate that more than 75% of patients experienced an improvement in their tinnitus symptoms as measured by both the Tinnitus Handicap Inventory and the Tinnitus Functional Index.

- The mean improvements in tinnitus scores from baseline to final treatment visit were statistically significant (p<0.001)
- The therapeutic changes observed exceeded values considered to be clinically meaningful
- The therapeutic benefit was sustained for at least 12 months after treatment cessation

Safety and tolerability of the device was confirmed, with only minor and transient side effects reported.

Neuromod’s approach represents a promising breakthrough in the treatment of tinnitus, an unmet medical need that affects more than 10% of the population.

Comfortable & easy to use

Lenire™ comprises of three main components:

1. The controller is a lightweight, handheld device that controls the timing and intensity of the treatment
2. The tonguetip® is a proprietary intra-oral device, ergonomically designed to sit comfortably in the closed mouth, that delivers mild electrical pulses to the trigeminal nerve endings on the anterior dorsal surface of tongue
3. Bluetooth headphones deliver a customised sound stimulus to the auditory nerve

Convenient & easy to prescribe

Lenire™ is customised by the clinician to the unique auditory profile of the patient. Following the initial consultation and fitting, the patient self-administers the treatment at home. Treatment time is 30 to 60 minutes per day for at least 10 weeks. Therapeutic benefit seen in clinical trials was achieved without concomitant counselling or therapy.

The treatment is suitable for adults over 18 years of age, who have experienced chronic tinnitus for at least three months before initiating treatment, and can be used safely in patients with hyperacusis.